discloses a controlled release carrier for the formulation of the injectable drug. Formulation pharmaceutically active agent, high viscosity liquid carrier material (the HVLCM), lactic acid-based polymer like poly (lactic acid) (glycolic acid), such as sucrose acetate isobutyrate (sucrose acetate isobutyrate), and compositions 1 atmosphere including an organic solvent to keep the monophasic form at 25 . Agent is released immediately after administration, as a result, less than 10% of the drug (e.g. 2-8%) is released in the first 5 hours until 5 hours to 7 days after the administration of 10% to 80% of the drug It is released in the period and 10% to 40% of the drug is gradually released over a period of 7 days to 28 days of the period from the initial administration. Agent may be an anti-schizophrenic agent delivered by injection.FIELD 30注入可能薬剤の制御放出用担体処方物を開示する。処方物は、薬学的活性剤、スクロースアセテートイソブチレート(sucrose acetate isobutyrate)のような高粘性液体キャリア材料(HVLCM)、乳酸系ポリマー様ポリ(乳酸)(グリコール酸)、および組成物を1気圧25℃で単相性形態に維持する有機溶媒を含む。薬剤は投与後すぐに放出され、その結果、薬剤の10%未満(例えば2~8%)が最初の5時間で放出され;薬剤の10%~80%が投与後5時間~7日目までの期間に放出され;また薬剤の10%~40%が初期投与から7日~28日目の期間にわたり徐々に放出される。薬剤は、注射により送達される抗統合失調症剤であってよい。【選択図】図30
